Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHRONOS-4: copanlisib plus standard immunochemotherapy in relapsed indolent non-Hodgkin lymphoma
jRCT2080223744Phase 3Completed
- Sponsor
- Bayer
- Start
- Dec 2017
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of copanlisib in non-Hodgkin lymphoma (NHL), follicular lymphoma (FL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and 3 more (4 arms), sponsored by Bayer. Primary endpoint: Progression-free survival (PFS). Started Dec 2017; status: completed.
02
Drugs
copanlisib
03
Conditions
non-Hodgkin lymphoma (NHL)follicular lymphoma (FL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Lymphoplasmacytic Lymphoma (LPL)Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on jRCT2080223744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223744.